Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150013 | 1.00 | FFAR1 (0.49) | FFAR1GRM4SLC9A1TPMTKMO | |
| SCHEMBL6994971 | 1.00 | FFAR1 (0.49) | FFAR1GRM4SLC9A1TPMTKMO | |
| SCHEMBL8150011 | 1.00 | FFAR1 (0.49) | FFAR1GRM4SLC9A1TPMTKMO | |
| SCHEMBL29134885 | 0.88 | FFAR1 (0.43) | FFAR1GRM4SLC9A1KMOMEN1 | |
| SCHEMBL30015566 | 0.88 | FFAR1 (0.43) | FFAR1GRM4SLC9A1KMOMEN1 | |
| SCHEMBL23357835 | 0.88 | FFAR1 (0.43) | FFAR1GRM4SLC9A1KMOMEN1 | |
| SCHEMBL29302328 | 0.88 | FFAR1 (0.49) | FFAR1GRM4SLC9A1ALDH1A1LMNA | |
| SCHEMBL29134884 | 0.88 | FFAR1 (0.43) | FFAR1GRM4SLC9A1KMOMEN1 | |
| SCHEMBL24737993 | 0.88 | GRM4 (0.47) | FFAR1GRM4SLC9A1MAPT | |
| SCHEMBL28855849 | 0.82 | SLC9A1 (0.49) | FFAR1GRM4SLC9A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| CN-107734969-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 美国陶氏益农公司 | 2018-02-23 | — | — | CN | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6251910-B1 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | ASTRAZENECA UK LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | FFAR1 1708/4885GRM4 1504/4885SLC9A1 354/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | FFAR1 1881/4885GRM4 1051/4885SLC9A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.